Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Bullish +75

Equitable Trust Co. Buys Shares of 12,912 Boston Scientific Corporation ...

AI-generated analysis

πŸ“ˆ Equitable Trust Co. initiated a new position by buying 12,912 shares of BSX valued at roughly $810,000.

πŸ“Š Whipplewood Advisors LLC increased its stake by 1,791.7%, while Resona Asset Management added to a $29 million holding.

πŸ‘” Director Edward J. Ludwig bought 3,580 shares for $202,914, increasing his personal position by 16.44%.

πŸ’° Insiders purchased 9,800 shares worth $554,012 over the last three months, indicating internal confidence.

πŸ“‰ BSX reported Q1 revenue of $5.20 billion, up 11.6% year-over-year, beating consensus estimates.

πŸ’΅ The company posted $0.80 EPS, surpassing analyst expectations of $0.79 by a penny.

🏦 Boston Scientific achieved a net margin of 17.29% and a return on equity of 19.17%.

πŸ”„ Management authorized a new $5.00 billion share repurchase program to buy back up to 6.4% of shares.

πŸ“ˆ Analysts forecast full-year EPS of 3.36, slightly higher than the company's guidance range.

πŸ₯ The medical device giant focuses on less-invasive procedures for cardiovascular and urologic conditions.

Bullish Signals
  • Equitable Trust Co. initiated a new position in BSX by purchasing 12,912 shares valued at approximately $810,000.
  • Whipplewood Advisors LLC significantly boosted its holdings by 1,791.7%, adding 645 shares to its portfolio.
  • Resona Asset Management Co. Ltd. increased its stake by 2.0%, now holding shares worth $29,139,000.
  • Director Edward J. Ludwig purchased 3,580 shares for a total of $202,914.40, increasing his position by 16.44%.
  • Insiders have collectively purchased 9,800 shares worth $554,012 in the last three months.
  • The company reported Q1 revenue of $5.20 billion, representing an 11.6% increase compared to the same quarter last year.
  • Boston Scientific beat analyst earnings estimates with $0.80 EPS versus a consensus of $0.79.
  • The firm achieved a net margin of 17.29% and a return on equity of 19.17% during the quarter.
  • Management authorized a new $5.00 billion share repurchase program, allowing the purchase of up to 6.4% of outstanding shares.
  • The company's Q2 2026 EPS guidance of $0.820-$0.840 aligns closely with sell-side analyst forecasts of $3.36 for the fiscal year.
Full Analysis
Equitable Trust Co. established a new position in Boston Scientific Corporation (BSX) during the first quarter by purchasing 12,912 shares valued at approximately $810,000. Several other institutional investors also increased their stakes, including Whipplewood Advisors LLC, which boosted its holdings by over 1,700%, and Resona Asset Management Co. Ltd., adding to a position worth nearly $29 million. Collectively, institutional investors own 89.07% of the company's outstanding stock. Insider trading activity shows bullish sentiment as directors Edward J. Ludwig and Cheryl Pegus purchased shares totaling over $300,000 in late May. In the last three months, insiders have collectively bought 9,800 shares worth approximately $554,000, representing a 16.44% increase for Director Ludwig. Company insiders currently hold 0.34% of the total stock. Financially, Boston Scientific reported strong quarterly results with revenue of $5.20 billion, an 11.6% year-over-year increase, and earnings per share of $0.80 that beat analyst estimates. The company has authorized a new $5.00 billion share repurchase program, signaling management's confidence in the stock's valuation and commitment to returning capital to shareholders.